Basit öğe kaydını göster

dc.contributor.authorZeybek, Ayse Cigdem Aktuglu
dc.contributor.authorCansever, Mehmet Serif
dc.contributor.authorHaberle, Johannes
dc.contributor.authorKiykim, Ertugrul
dc.contributor.authorZubarioglu, Tanyel
dc.contributor.authorCelkan, Tiraje
dc.date.accessioned2021-03-04T17:34:42Z
dc.date.available2021-03-04T17:34:42Z
dc.date.issued2018
dc.identifier.citationKiykim E., Zubarioglu T., Cansever M. S. , Celkan T., Haberle J., Zeybek A. C. A. , "Coagulation Disturbances in Patients with Argininemia", ACTA HAEMATOLOGICA, cilt.140, sa.4, ss.221-225, 2018
dc.identifier.issn0001-5792
dc.identifier.otherav_8653d60c-fef0-4544-aabd-6815e8a8dfe4
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/91283
dc.identifier.urihttps://doi.org/10.1159/000493678
dc.description.abstractBackground: Argininemia is an autosomal recessive urea cycle disorder (UCD). Unlike other UCD, hyperammonemia is rarely seen. Patients usually present in childhood with neurological symptoms. Uncommon presentations like neonatal cholestasis or cirrhosis have been reported. Although transient elevations of liver transaminases and coagulopathy have been reported during hyperammonemia episodes, a permanent coagulopathy has never been reported. Methods: In this retrospective study, coagulation disturbances are examined in 6 argininemia patients. All of the patients were routinely followed up for hepatic involvement due to argininemia. Laboratory results, including liver transaminases, albumin, prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), and clotting factor levels, were assessed in all of the patients. Results: All of the patients had a prolonged PT and an in-creased INR, while none of the patients had a prolonged aPTT. Five patients had slightly elevated liver transaminases. A liver biopsy was performed in 1 patient but neither cirrhosis nor cholestasis was documented. Five of the 6 patients had low factor VII and factor IX levels, while other clotting factors were normal. Conclusions: Argininemia patients should be investigated for coagulation disorders even if there is no apparent liver dysfunction or major bleeding symptoms. (C) 2018 S. Karger AG, Basel
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectHEMATOLOJİ
dc.titleCoagulation Disturbances in Patients with Argininemia
dc.typeMakale
dc.relation.journalACTA HAEMATOLOGICA
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume140
dc.identifier.issue4
dc.identifier.startpage221
dc.identifier.endpage225
dc.contributor.firstauthorID249551


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster